
Researchers Genetically Engineer Flu Virus to Create New Vaccine Candidate
As 49 states report widespread flu activity for the second week in a row, researchers at UCLA offer hope in the form of a new flu vaccine candidate.
For the second week in a row, 49 states reported widespread influenza activity; however, during this severe flu season, one new study is offering hope in the form of a new flu vaccine candidate.
During week 2 ending January 13, 2018, the Centers for Disease Control and Prevention (CDC) reported that the proportion of outpatient visits for influenza-like illness (ILI) rose from 5.8% to 6.3% since the prior week, while all 10 national regions saw ILI activity at or above their baseline levels. The weekly FluView
In South Carolina, more than 3 times as many flu deaths have been reported as of week 2 in the 2017-2018 flu season than were reported at the same time last season. By week 2 of the
In Texas,
In a previous
The study team spent 4 years studying the flu virus’s genome, locating and then deactivating the sequences that allow the virus to prevent interferon induction. "By disabling these interferon-evasion functions, the engineered virus is weakened in typical hosts. At the same time, however, due to interferon stimulation, the engineered virus generates very strong immune responses,” the study’s first author Yushen Du, PhD, explained in a recent
"With this approach, the safety and efficacy requirement of vaccines can potentially be achieved simultaneously,” senior author Ren Sun, PhD added. “In traditional vaccine development, one is usually sacrificed for the other.”
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.